Upgrade to SI Premium - Free Trial

Inspire Medical Systems (INSP) Tops Q4 EPS by 2c, Revenues Beat; Offers FY2) Revenue Guidance Above Consensus

February 25, 2020 4:50 PM

Inspire Medical Systems (NYSE: INSP) reported Q4 EPS of ($0.38), $0.02 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $26.9 million versus the consensus estimate of $23.84 million.

Recent Business Highlights

“The Inspire team and the healthcare providers who prescribe and support Inspire therapy continue to be fully committed to delivering positive and consistent patient outcomes for those with untreated Obstructive Sleep Apnea,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. “We continue to execute on our balanced commercial growth strategy, which is primarily focused on the U.S. market, with the objective of first, increasing patient flow at existing centers, and second, training and opening new implanting centers. We are confident that we remain well-positioned for long-term success based on our focus on improving utilization and our conversion rate, further advancements in reimbursement, including Medicare, a growing body of clinical evidence, and a robust R&D platform.”

GUIDANCE:

Inspire Medical Systems sees FY2020 revenue of $115-119 million, versus the consensus of $108.8 million.

For earnings history and earnings-related data on Inspire Medical Systems (INSP) click here.

Categories

Corporate News Earnings Guidance Hot Guidance Management Comments

Next Articles